Asiaticoside(Synonyms: 积雪草苷)

天然产物 糖类和糖苷 Saccharides and Glycosides

Asiaticoside;(Synonyms: 积雪草苷) 纯度: 99.72%

Asiaticoside 是从积雪草中分到的三萜皂苷化合物,在瘢痕疙瘩成纤维细胞中,通过活化 Smad7,抑制 TGF-βRI 和 TGF-βRII,抑制 TGF-β/Smad 信号通路;Asiaticoside 具有抗氧化、抗炎、抗溃疡等功效。

Asiaticoside(Synonyms: 积雪草苷)

Asiaticoside Chemical Structure

CAS No. : 16830-15-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg) ; Apply now ;
10;mM;*;1 mL in DMSO ¥550 In-stock
10 mg ¥500 In-stock
50 mg ¥1800 In-stock
100 mg ¥3100 In-stock
200 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Asiaticoside 相关产品

bull;相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • NF-kappa;B Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • TGF-beta/Smad Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Human Endogenous Metabolite Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Glycoside Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Ferroptosis Compound Library
  • Terpenoids Library
  • Pyroptosis Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Angiogenesis Related Compound Library
  • Mitochondria-Targeted Compound Library
  • Transcription Factor Targeted Library
  • Food-Sourced Compound Library

生物活性

Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.

IC50 Target

Human Endogenous Metabolite

;

体外研究
(In Vitro)

Asiaticoside (0, 100, 250, and 500 mg/L) dose-dependently inhibits keloid fibroblasts proliferation. Asiaticoside (100, 250, and 500 mg/L) decreases the expression of collagen protein and mRNA, reduces the expression of TGF-bRI, TGF-bRII protein, and mRNA, increases the expression of Smad7, but does not affect Smad2, Smad3, Smad4, phosphorylated Smad2, and phosphorylated Smad3 in keloid fibroblasts[1]. Asiaticoside (12.5 and 50, and 25 and 50 µg/mL) prevents endothelial cells from hypoxia-induced inhibition of cell viability and NO production. Asiaticoside (50 µg/mL) also protects endothelial cells from hypoxia-induced apoptosis and upregulates and phosphorylation of AKT/eNOS in hypoxia-exposed HPAECs[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Asiaticoside (50 mg/kg daily) blocks the development of hypoxic pulmonary hypertension (PH), cardiovascular remodeling and endothelial cell injury in rats with pulmonary hypertension[2]. Asiaticoside (5, 15 or 45 mg/kg, p.o.) improves the learning and memory deficit, protects hippocampi against the impairment, decreases Aβ deposits in the hippocampus, and ameliorates impaired subcellular structure in rats treated with Aβ oligomers[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

959.12

Formula

C48H78O19

CAS 号

16830-15-2

中文名称

积雪草苷

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20deg;C 3 years
4deg;C 2 years
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : 50 mg/mL (52.13 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0426 mL 5.2131 mL 10.4262 mL
5 mM 0.2085 mL 1.0426 mL 2.0852 mL
10 mM 0.1043 mL 0.5213 mL 1.0426 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 4.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 5.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 6.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 7.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 8.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 9.

    请依序添加每种溶剂:;5% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 50% saline

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

  • 10.

    请依序添加每种溶剂:;5% DMSO ;; 95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Tang B, et al. Asiaticoside suppresses collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. h Dermatol Res. 2011 Oct;303(8):563-72.

    [2]. Wang X, et al. Effect of asiaticoside on endothelial cells in hypoxia‑induced pulmonary hypertension. Mol Med Rep. 2018 Feb;17(2):2893-2900.

    [3]. Zhang Z, et al. Asiaticoside ameliorates β-amyloid-induced learning and memory deficits in rats by inhibiting mitochondrial apoptosis and reducing inflammatory factors. Exp Ther Med. 2017 Feb;13(2):413-420.

Cell Assay
[1]

Cells are seeded at a density of 2-9 × 104 cells/mL into 24-well plates for cell viability, 60-mm plates for RNA and protein analysis in DMEM containing 10% FBS (DMEM/10% FBS). After 24 h, medium is removed and cells are placed in serum-free DMEM. After 48 h, different concentrations of Asiaticoside in DMEM/10% FBS are added simultaneously to cells. Control cells are grown in DMEM/10% FBS without the addition of Asiaticoside. At different time points, the fibroblasts are harvested for analysis[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Rats[3] Sprague-Dawley rats are used to establish the Alzheimer’s disease (AD) model. Asiaticoside is administered orally at 5, 15 or 45 mg/kg body weight per day for 7 days. The learning and memory function of the rats are evaluated by the MWM test 7 days after surgery. The swimming pool (180 cm in diameter) is maintained at 22-24°C, and divided into four quadrants with equal size. A hidden platform is placed in the center of one quadrant. Each of the cardinal points of these four quadrants is randomLy selected as the start location. On the pre-test day, rats are allowed to swim freely for 120 sec. During the test (days 1-4), each rat is subjected to 8 trials each day. The trial begins when a rat is placed in the pool, and ended when the rat finds the platform. The escape latency is recorded. If a rat fails to find the platform within 120 sec, the trial is terminated and the escape latency is recorded as 120 sec, and the rat is guided to the platform. On day 5, the swimming path is recorded by a video recording system, and the digital images are analyzed by the water maze software. In addition, the probe test is performed, in which the platform is removed, and the rat is allowed to swim freely in the pool for 120 sec. The swimming time in the target quadrant is recorded[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Tang B, et al. Asiaticoside suppresses collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. h Dermatol Res. 2011 Oct;303(8):563-72.

    [2]. Wang X, et al. Effect of asiaticoside on endothelial cells in hypoxia‑induced pulmonary hypertension. Mol Med Rep. 2018 Feb;17(2):2893-2900.

    [3]. Zhang Z, et al. Asiaticoside ameliorates β-amyloid-induced learning and memory deficits in rats by inhibiting mitochondrial apoptosis and reducing inflammatory factors. Exp Ther Med. 2017 Feb;13(2):413-420.

发表回复